Compare TNYA & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNYA | HYI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 135.2M |
| IPO Year | 2021 | 2010 |
| Metric | TNYA | HYI |
|---|---|---|
| Price | $0.54 | $9.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 68.0K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.59% |
| EPS Growth | ★ 54.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $9.61 |
| 52 Week High | $2.35 | $11.61 |
| Indicator | TNYA | HYI |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 27.95 |
| Support Level | $0.53 | N/A |
| Resistance Level | $0.82 | $10.66 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 12.65 | 16.05 |
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.